JACC Asia, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
Язык: Английский
New England Journal of Medicine, Год журнала: 2024, Номер unknown
Опубликована: Авг. 31, 2024
BackgroundCurrent treatment recommendations for patients with heart failure and secondary mitral regurgitation include transcatheter edge-to-edge repair mitral-valve surgery. Data from randomized trials comparing these therapies are lacking in this patient population.MethodsIn noninferiority trial conducted Germany, who continued to have symptoms despite guideline-directed medical therapy were randomly assigned, a 1:1 ratio, undergo either (intervention group) or surgical replacement (surgery group). The primary efficacy end point was composite of death, hospitalization failure, reintervention, implantation an assist device, stroke within 1 year after the procedure. safety major adverse events 30 days procedure.ResultsA total 210 underwent randomization. mean (±SD) age 70.5±7.9 years, 39.9% women, left ventricular ejection fraction 43.0±11.7%. Within year, at least one components occurred 16 96 available data (16.7%) intervention group 20 89 (22.5%) surgery (estimated difference, −6 percentage points; 95% confidence interval [CI], −17 6; P<0.001 noninferiority). A end-point event 15 101 (14.9%) 51 93 (54.8%) −40 CI, −51 −27; P<0.001).ConclusionsAmong regurgitation, noninferior respect rehospitalization stroke, device ventricle year. (Funded by Abbott Vascular; MATTERHORN ClinicalTrials.gov number, NCT02371512.)
Язык: Английский
Процитировано
42
Trends in Cardiovascular Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a transformative therapy for mitral regurgitation (MR), addressing the unmet needs of patients unsuitable surgery. Landmark trials such EVEREST II, COAPT, and MITRA-FR have established safety efficacy M-TEER, in both with primary (PMR) secondary MR (SMR). Recent trials, including RESHAPE-HF2 MATTERHORN, expanded our understanding refueled discussions regarding patient selection appropriate treatment indications SMR. These also contributed to discussion SMR phenotypes most M-TEER. This review summarizes evidence from pivotal discusses selection, device advancements, potential future directions, outlines ongoing that may shape clinical practice.
Язык: Английский
Процитировано
2
КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Treating anterior and bileaflet mitral valve disease in patients with primary or degenerative regurgitation (DMR) is considered more challenging than posterior leaflet repair. The aim of this analysis was to evaluate the impact anterior, posterior, on outcomes following transcatheter edge-to-edge repair (M-TEER) EXPANDed studies. a pooled, patient-level subjects undergoing M-TEER MitraClip G3 G4 system as part contemporary EXPAND Subjects DMR were categorized according echocardiography core laboratory-assessed prolapse flail location into (prolapse at P1, P2, and/or P3), A1, A2, A3) any combination A3 P3). Key assessed included procedural outcomes, 30-day major adverse events, 1-year (MR) severity. Of 2,205 EXPANDed, 556 had location. Three hundred eighty-nine 106 61 disease. All groups experienced low device procedure times high success rates (defined discharge MR ≤ 2+). Thirty-day events across all (posterior, 4.4% [17 388]; 3.8% [4 105]; bileaflet, 6.6% 61]; P = 0.65). Through 1 year, showed significant reduction severity from baseline (MR 1+ 82% [179 219]; 93% [53 57]; 97% [28 29]). Results studies demonstrate that treated improvements regardless flail.
Язык: Английский
Процитировано
2
European Journal of Heart Failure, Год журнала: 2025, Номер unknown
Опубликована: Янв. 8, 2025
Abstract Aims Secondary mitral regurgitation (SMR) and tricuspid (TR) are the most common valvular heart diseases in patients with failure (HF). Transcatheter edge‐to‐edge repair (TEER) devices designed for treating MR TR have been successfully tested randomized controlled trials, but methodological issues often challenged their interpretation. This manuscript aimed to provide an overview of TEER registries on SMR HF, highlighting key features, describing clinical characteristics outcomes receiving these devices, exploring available data limitations. Methods results PubMed, Web Science, EMBASE were searched reporting or TR. Registries excluded if single‐centre <100 patients. Twenty‐six (46% prospective, 12% ongoing), including a total cohort 18 925 patients, retrieved SMR, six (50% retrospective, 33% ongoing) reported use 1412 Limited geographical representativity outside North America Europe, high number missing values, inconsistency main existing evidence Conclusion represent source setting where it is difficult conduct trials. However, limitations design, patient characterization, restrain use. A novel conceptual framework future prospective registries, as proposed this document, might inform current practice, address relevant questions trial design.
Язык: Английский
Процитировано
1
КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2025, Номер 18(3), С. 311 - 321
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2024, Номер 17(13), С. 1559 - 1573
Опубликована: Июль 1, 2024
Язык: Английский
Процитировано
9
КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2024, Номер 17(7), С. 890 - 903
Опубликована: Апрель 1, 2024
Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes the PASCAL system in post-market setting have not been established. The authors report 30-day and 1-year outcomes from MiCLASP (Transcatheter Repair of Regurgitation Edwards Transcatheter Valve System) European clinical follow-up study. Patients symptomatic, clinically significant MR were prospectively enrolled. primary safety endpoint was events committee-adjudicated composite major adverse event rate effectiveness echocardiographic core laboratory-assessed severity at discharge compared baseline. Clinical, echocardiographic, functional, quality-of-life assessed 1 year. A total 544 enrolled (59% functional MR, 30% degenerative MR). 6.8%. reduction baseline to sustained year 98% achieving ≤2+ 82.6% ≤1+ (all P < 0.001 vs baseline). One-year Kaplan-Meier estimate survival 87.3%, freedom heart failure hospitalization 84.3%. Significant improvements observed year, including 71.6% NYHA class I/II, 14.4-point increase Kansas City Cardiomyopathy Questionnaire score, 24.2-m improvement 6-minute walk distance this large cohort study demonstrate continued M-TEER setting. Results high hospitalization, reduction, symptoms, capacity, quality life.
Язык: Английский
Процитировано
6
JACC Heart Failure, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
5
Clinical Research in Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 14, 2025
Язык: Английский
Процитировано
0
Aktuelle Kardiologie, Год журнала: 2025, Номер 14(01), С. 40 - 46
Опубликована: Фев. 1, 2025
Zusammenfassung Die Therapie der Mitralklappeninsuffizienz (MI) mittels transvenöser Mitralklappenprothesen (TMVR) bietet eine vielversprechende minimalinvasive Option für Hochrisikopatienten, die keine Operation erhalten können. komplexe Anatomie Mitralklappe und ihre Nähe zum linksventrikulären Ausflusstrakt (LVOT) stellen jedoch technische Herausforderungen dar. Verkalkungen des Mitralklappenanulus erschweren zudem Behandlung. TMVR-Systeme zeigen Ergebnisse, wobei innovative Verankerungsmechanismen Risiken, wie LVOT-Obstruktion, minimieren. Dennoch bleibt Patientenauswahl problematisch, da viele Patienten aufgrund anatomischer Einschränkungen TMVR ungeeignet sind. Zukünftige Entwicklungen in Prothesentechnologie Zugangsverfahren könnten diese Therapieoption weiter verbessern. Langfristige Daten technologische Fortschritte sind notwendig, um als Standardbehandlung zu etablieren von MI revolutionieren.
Процитировано
0